Products for Research Use Only
RegisterLogin

(Pro3) GIP, human (TFA)

CAT: 0804-HY-P3584A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P3584A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes[1][2].
Product Name Alternative
(Pro3) Gastric Inhibitory Peptide, human (TFA)
UNSPSC
12352209
Target
Insulin Receptor
Type
Peptides
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/pro3-gip-human-tfa.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL
Smiles
O=C([C@@H](N)CC1=CC=C(O)C=C1)N[C@H](C(N2[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCC(N)=O)=O)[C@@H](C)O)=O)[C@H](CC)C)=O)CC(N)=O)=O)CC3=CNC=N3)=O)CCCCN)=O)CC4=CNC5=CC=CC=C45)=O)CC(O)=O)=O)CC(N)=O)=O)CCCCN)=O)CCCCN)=O)=O)CCCCN)=O)CCC(N)=O)=O)C)=O)CC(C)C)=O)CC(C)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(N)=O)=O)C(C)C)=O)CC8=CC=CC=C8)=O)CC(O)=O)=O)CCC(N)=O)=O)CCC(N)=O)=O)CC9=CNC=N9)=O)[C@H](CC)C)=O)CCCCN)=O)CC(O)=O)=O)CCSC)=O)C)=O)[C@H](CC)C)=O)CO)=O)CC%10=CC=C(O)C=C%10)=O)CC(O)=O)=O)CO)=O)[C@H](CC)C)=O)CC%11=CC=CC=C%11)=O)[C@@H](C)O)=O)=O)CCC2)=O)C.OC(C(F)(F)F)=O.[x]
Molecular Formula
C226H338N60O64S.xC2HF3O2
Molecular Weight
4951.53 (free base)
References & Citations
[1]Victor A Gault, et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3) GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 2005, 54, 8.|[2]A H Sparre-Ulrich, et al. Species-specific action of (Pro3) GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. Br J Pharmacol. 2016, 173, 1.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported

Related Products

CatalogName
HY-P3584(Pro3) GIP, human
HY-P1433[Pro3]-GIP (Rat)
HY-P1434-01[Pro3]-GIP (mouse)
HY-P0276A-01GIP, human (TFA)
HY-P5390A-01GIP, rat (TFA)
HY-P10138A-01Human GIP (3-30), amide (TFA)
HY-P2541A-01GIP (1-30) amide, porcine (TFA)
HY-P0276-01GIP, human
HY-P2542-01GIP (3-42), human
HY-P10972GIP (22-51) human

Alternative Products

CatalogName
MBS5818235(Pro3) GIP, human
GTR19150192-01(Pro3) GIP, human acetate
GTR19067668-01(Pro3) Gastric Inhibitory Peptide (GIP), human
GTR19036568-01GIP, human TFA
M30265GIP (1-30) amide (Human) (TFA)
MBS5789286GIP (1-30) amide (Human)(TFA)
M30675[Pro3]-GIP (Rat)
M30674[Pro3]-GIP (Mouse)
MBS5827281[Pro3]-GIP (Mouse) acetate
5838/1[Pro3]-GIP (Mouse) 1 mg

Popular Products